Implant Sciences’ (IMSC) CEO Glenn Bolduc on Q4 2014 Results – Earnings Call Transcript

Implant Sciences’ (IMSC) CEO Glenn Bolduc discusses Q4 2014 results on a conference call held on September 19, 2014…


Glenn Bolduc – Chairman, President, Chief Executive Officer

Roger Deschenes – Chief Financial Officer

Darryl Jones – VP, Sales and Marketing

Bill McGann – Chief Operating Officer


Mark Jordan – Noble Financial

Kenneth Rybicki – Private Investor

Joe Munda – Sidoti & Company

Patrick Mayor – Private Investor

Eric Panzik – Private Investor

Mark Wilcheck – Private Investor

Sean Sullivan – Private Investor

Implant Sciences Corporation (OTCQB:IMSC) Q4 2014 Results Earnings Conference Call September 29, 2014 4:15 PM ET


Good day, ladies and gentlemen, and welcome to the Q4 2014 Implant Sciences Corporation earnings conference call. My name is Whitney, and I will be your operator for today. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. (Operator Instructions). As a reminder, this call is being recorded for replay purposes.

I would now like to turn the conference over to your host for today, Mr. Glenn Bolduc, President and Chief Executive Officer. Please, proceed.

Glenn Bolduc – Chairman, President, Chief Executive Officer

Thank you very much, Whitney. And I would like to thank everyone to Implant Sciences’ fourth quarter fiscal 2014 earnings conference call. We are going to do this a little differently today. I am going to offer some brief remarks at the beginning, ask Roger to review the financials with you and then I will offer more description on the activities in the business. We also welcome those of you who are joining us via a webcast today.

On the call with me this afternoon are Dr. Bill McGann, our Chief Operating Officer; Roger Deschenes, who I just mentioned a moment ago, our Chief Financial Officer, and Dr. Darryl Jones, our Vice President of Sales and Marketing. In many regards, fiscal 2014 was a very good year for the company. If a few things had happened faster that we will discuss with you, we believe that we would be talking about our best year ever.

ALSO READ:   Big Lots' (BIG) CEO David Campisi on Q2 2014 Results - Earnings Call Transcript

We did achieve two major approvals. Addition to the qualified product section of the air cargo screening technology list and certification by STAC in France. I embarrassed myself once telling you what STAC was, just know it’s the likely equivalent to TSA in France. We continue to make progress on other certifications and in August, we passed our biggest milestone to-date when the QS-B220, our benchtop was added to the TSA’s qualified product list, also known as the QPL.

Our relationship with the Transportation Security Laboratory remains very strong, and in April of this year we announced that we have signed a new cooperative research and development agreement with the TSL to use the benchtop as a “gold standard” trace detector in the development of the next generation of trace detection requirements. With this agreement, Implant Sciences has moved from a company chasing performance standards to one that is truly helping to define them.

Despite the delays in certifications, we were able to achieve significant growth in new international sales bookings. The missing component from our original plan was sales to the U.S. government. We have reported that to you previously. Our remaining steps for this are executing an indefinite delivery, indefinite quantity or IDIQ contract with the TSA and then securing orders against that IDIQ. The history of this process again demonstrates the difficulties in predicting exact timelines. However, we believe that the IDIQ is on track and we remain confident regards to an anticipated procurement award in the near future.

We believe that fiscal 2014 has positioned Implant Sciences for immediate and long-term success and we remain excited about the opportunities that are in front of us. Roger will provide a brief financial report on the company’s results for the quarter and fiscal year ended June 30, 2014. We will then provide deeper insight into the non-financial aspects of the company, its operations, and our plans going forward. Following our prepared marks, we will open the call up for questions from today’s participants.

ALSO READ:   Groupon's (GRPN) CEO Eric Lefkofsky on Q2 2014 Results - Earnings Call Transcript

Roger, why don’t you take over?

Roger Deschenes – Chief Financial Officer

Okay. Thank you, Glenn. A little bit of housekeeping. During this afternoon’s presentation, we will make forward-looking statements concerning upcoming events and our expectations regarding the company’s financial performance. Each time we do we’ll try to identify these statements with words such as expect, believe, anticipate and other words that indicate potential events. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those stated in the forward-looking statements.

Pages: First |1 | ... | | Last | View Full Transcript

Leave a Comment

Scroll to Top